IP Library › Granted Patent US 12,065,437
Granted Patent B2
US 12,065,437 · App. 17/192,985 · Granted Aug 20, 2024

Biaryl kinase inhibitors

Inventors: Guanglin Luo (Newtown, PA); Carolyn Diane Dzierba (Middletown, CT); John E. Macor (Washington Crossing, PA)
Assignee: Bristol-Myers Squibb Company
C07D471/04A61K31/4427A61K31/50A61P25/28C07C233/25C07D213/30C07D213/34C07D213/57C07D213/61C07D213/64C07D213/73C07D213/74C07D213/75C07D213/80C07D215/14C07D237/08C07D239/26C07D309/18C07D309/22C07D401/04C07D401/14C07D413/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,065,437
App. No.
17/192,985
Granted
Aug 20, 2024
Kind
B2
Abstract

The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.

Claims (4)

1. A method of treating diabetic neuropathy, the method comprising administering to a patient in need thereof a therapeutically effective amount of (S)-1-((2′,6-bis(difluoromethyl)-[2,4′-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amine, or a pharmaceutically acceptable salt thereof, and an anti-diabetic agent.

2. The method of claim 1 , wherein the anti-diabetic agent is a biguanide.

3. The method of claim 1 , wherein the anti-diabetic agent is a DPP4 inhibitor.

4. The method of claim 1 , wherein the anti-diabetic agent is an SLGT2 inhibitor.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 5, 2021
From: RUTHERFORD, RYAN; GOETZEL, CAITLIN
To: COSMIC PET LLC
Reel/Frame 055503/0457 →